#ASCO21: Ahead of August PDUFA date, Astellas and Seagen sweeten Padcev pitch with new data

Astellas and Seagen made waves back in 2019 when they nabbed conditional approval for their Nectin-4 targeting therapy Padcev in urothelial cancer. Now, as the FDA considers a full approval and label expansion, the companies have some new data to share ahead of their August PDUFA date.